Peizhi Luo
Chief Executive Officer at ADAGENE INC.
Net worth: 22 M $ as of 2024-04-29
Peizhi Luo active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ADAGENE INC. | Chief Executive Officer | 2011-10-31 | - |
| Chairman | 2018-01-31 | - | |
| Chief Tech/Sci/R&D Officer | - | - | |
| Founder | 2011-02-24 | - |
Career history of Peizhi Luo
Former positions of Peizhi Luo
| Companies | Position | Start | End |
|---|---|---|---|
Abmaxis, Inc.
 Abmaxis, Inc. Pharmaceuticals: MajorHealth Technology Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA. | Director/Board Member | 1999-12-31 | 2008-11-05 |
| Chief Tech/Sci/R&D Officer | 1999-12-31 | 2008-11-05 | |
| Founder | 1999-12-31 | 2008-11-05 | |
| President | 1999-12-31 | 2008-11-05 | |
| XENCOR, INC. | Corporate Officer/Principal | 1998-06-30 | 2000-07-31 |
| MERCK & CO., INC. | Corporate Officer/Principal | - | - |
Training of Peizhi Luo
| The University of Chicago | Doctorate Degree |
| Peking University | Undergraduate Degree |
| Chinese Academy of Sciences | Graduate Degree |
Statistics
International
| United States | 5 |
| China | 4 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ADAGENE INC. | Health Technology |
| XENCOR, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Private companies | 1 |
|---|---|
Abmaxis, Inc.
Abmaxis, Inc. Pharmaceuticals: MajorHealth Technology Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA. | Health Technology |
- Stock Market
- Insiders
- Peizhi Luo
- Experience